Mr. Yiqin Wu joined Chengdu New Radiomedicine Technology Co., Ltd. in 2023 and is the Chief Scientific Officer of the company. Mr. Wu is a PhD in Biochemistry from Boston College in United States and holds a bachelor’s and a master’s degree in Chemistry from Sun Yat-sen University in China. Dr. Wu was a Postdoctoral Fellow at The Scripps Research Institute, Senior Scientist for biological R&D at Syrrx Inc. (acquired by Takeda in 2005), Senior Scientist and Project Leader at Takeda Pharmaceuticals, Chief Scientist and Project Leader at Quanticel Pharmaceuticals (acquired by Celgene in 2015), Chief Scientist and Project Leader at Celgene (San Diego), a founding team member and Scientist and Vice President of R & D at T2YC, Director of the Translational Center at Beijing Global Health Drug Discovery Institute (GHDDI), and Chief Scientist at Eubulus Biotherapeutics.

Dr. Wu has over 20 years of experience in novel drug research and development. He has led many novel drug discovery projects in the areas of oncology, , diabetes, cardiovascular disease, neurodegenerative disease, inflammatory and immune disease, etc., among which three projects were advanced to clinical stages in Europe and the United States. He was also involved in the discovery of new drug Alogliptin for diabetes, which was approved by U.S. FDA in 2013.